Levosimendan Waymade (Levosimendan)

• Levosimendan is used as an inotropic agent in acute heart failure syndromes.
• Acute decompensated heart failure: improves cardiac output and reduces filling pressures.
• Cardiogenic shock: provides hemodynamic support when conventional therapy is insufficient.
• Post‑cardiac surgery low‑output syndrome: enhances contractility to facilitate weaning from mechanical support.

• Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby augmenting myocardial contractility without raising intracellular calcium concentrations. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing arterial and venous vasodilation, which reduces after‑load and improves cardiac output.

Levosimendan may cause a range of adverse reactions that clinicians monitor during therapy.

Common Side Effects

• Hypotension: drop in blood pressure, especially when combined with other vasodilators.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Flushing: transient warmth and redness of skin.
• Tachycardia: increased heart rate.
• Arrhythmia: non‑life‑threatening rhythm disturbances.

Serious or Rare Side Effects

• Severe hypotension: may require vasopressor support.
• Ventricular arrhythmias: potentially life‑threatening.
• Myocardial ischemia: chest pain or ECG changes.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Pulmonary edema: worsening respiratory status.
• Liver enzyme elevation: abnormal hepatic function tests.

• Before initiating levosimendan, clinicians should assess patient stability and monitor for specific risks.
• Monitor blood pressure: watch for hypotension, especially in patients receiving other vasodilators.
• Assess cardiac rhythm: be vigilant for arrhythmias during infusion.
• Evaluate renal function: adjust therapy if significant impairment is present.
• Avoid in severe hypotension: contraindicated when systolic pressure is markedly low.
• Use with caution with other inotropes: may potentiate cardiac effects.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Concomitant vasodilators (e.g., nitroglycerin): may cause severe hypotension.
• Other calcium sensitizers: increase risk of arrhythmia.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): raise plasma levosimendan levels.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt desired hemodynamic response.
• Diuretics: can affect electrolyte balance and renal function.
• ACE inhibitors: may enhance hypotensive effect.